Alvocidib

Summary

Alvocidib (CHEMBL428690) is a phase-3 clinical-stage small-molecule antineoplastic agent targeting CDK2 and CDK4; indicated across 19 conditions including lymphoma and plasma cell myeloma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 2 (CDK2, CDK4)
• Indications: 19 conditions
• Clinical trials: 58
• Chemistry: 401.8 Da · C21H20ClNO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL428690
Name	Alvocidib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5287969
ChEBI	CHEBI:47344
Molecular formula	C21H20ClNO5
Molecular weight	401.8
InChIKey	BIIVYFLTOXDAOV-YVEFUNNKSA-N

SMILES: CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O

IUPAC name: 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one

ChEBI definition: A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2’ position (the (−)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, antirheumatic drug, apoptosis inducer.

Also known as: Alvocidib, Alvocidib freebase, Flavopiridol, HL 275, HL-275, HMR 1275, HMR-1275, L 86 8275, L-868275, MDL 107,826A, MDL-107826A, NSC-649890

Parent form; salt/anhydrous children: CHEMBL2105698

Patent coverage: 7,239 distinct patent families (27,781 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 24,608 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CDK2	cyclin dependent kinase 2	Inhibition	7	71.1%	P24941
CDK4	cyclin dependent kinase 4	Inhibition	7.19	58%	P11802

Broader ChEMBL bioactivity targets: 179 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Rhodopsin kinase GRK7, Homeodomain-interacting protein kinase 4, Serine/threonine-protein kinase TAO2, Dual specificity protein kinase CLK1, Serine/threonine-protein kinase MAK, Cyclin-dependent kinase-like 5, Serine/threonine-protein kinase ICK, Serine/threonine-protein kinase VRK2, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Bromodomain testis-specific protein, Cyclin-dependent kinase 13, Receptor tyrosine-protein kinase erbB-2, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Cyclin-dependent kinase 5/CDK5 activator 1, Cyclin-dependent kinase 4/cyclin D1, Cyclin-dependent kinase 1/cyclin B1, Cyclin-dependent kinase 2/cyclin E1, Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma.

Bioactivity

ChEMBL activities: 511 potent at pChembl ≥ 5 of 521 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CILK1	9.16	Kd	0.69	nM	CHEMBL_ACT_7579762
CCNT1	9.15	Ki	0.7	nM	CHEMBL_ACT_29064286
CCNT1	8.85	IC50	1.4	nM	CHEMBL_ACT_29064281
CCNT1	8.6	IC50	2.5	nM	CHEMBL_ACT_16737181
CDK9	8.52	Ki	3	nM	CHEMBL_ACT_12622859
CCNT1	8.52	Ki	3	nM	CHEMBL_ACT_12622894
LARP7	8.52	Ki	3	nM	CHEMBL_ACT_19112063
CDK9	8.52	IC50	3	nM	CHEMBL_ACT_22758226
CDK9	8.52	IC50	3	nM	CHEMBL_ACT_24975154
CDK9	8.52	IC50	3	nM	CHEMBL_ACT_25539593
CDK4	8.48	Kd	3.3	nM	CHEMBL_ACT_7579447
CCNT1	8.43	IC50	3.7	nM	CHEMBL_ACT_18146977
CDK9	8.35	IC50	4.5	nM	CHEMBL_ACT_25611224
CCNT1	8.34	IC50	4.59	nM	CHEMBL_ACT_16385312
CCNT1	8.3	IC50	5	nM	CHEMBL_ACT_26327842
CCNT1	8.22	IC50	6	nM	CHEMBL_ACT_14659236
CDK17	8.22	Kd	6	nM	CHEMBL_ACT_17889582
CCNT1	8.22	IC50	6	nM	CHEMBL_ACT_26224807
CDK9	8.21	IC50	6.1	nM	CHEMBL_ACT_26163137
CDK9	8.19	Kd	6.4	nM	CHEMBL_ACT_2903861
CCNT1	8.19	Kd	6.4	nM	CHEMBL_ACT_29064328
CDK9	8.19	Kd	6.4	nM	CHEMBL_ACT_7579497
CDK9	8.15	Kd	7	nM	CHEMBL_ACT_17891286
CDKL5	8.15	Kd	7.1	nM	CHEMBL_ACT_7579572
CDK4	8.05	Kd	9	nM	CHEMBL_ACT_7579446
CDK7	8	IC50	10	nM	CHEMBL_ACT_22758219
CDK4	8	IC50	10	nM	CHEMBL_ACT_24788462
CDK1	8	IC50	10	nM	CHEMBL_ACT_24788532
CDK2	8	IC50	10	nM	CHEMBL_ACT_24788536
CDK9	8	IC50	10	nM	CHEMBL_ACT_24788541
CDK7	8	IC50	10	nM	CHEMBL_ACT_24975193
CDK7	8	IC50	10	nM	CHEMBL_ACT_25539597
CDK9	8	IC50	10	nM	CHEMBL_ACT_25980885
CCNT1	7.96	IC50	11	nM	CHEMBL_ACT_16737224
CCNT1	7.96	IC50	11	nM	CHEMBL_ACT_22967903
CCNT1	7.96	IC50	11	nM	CHEMBL_ACT_26281857
CAMKK1	7.72	Kd	19	nM	CHEMBL_ACT_1650008
CCNT1	7.7	IC50	20	nM	CHEMBL_ACT_18224282
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_18784877
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_19027223
CDK4	7.7	IC50	20	nM	CHEMBL_ACT_19112058
CCNT1	7.7	IC50	20	nM	CHEMBL_ACT_19112061
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_19258241
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_22967931
CDK4	7.7	IC50	20	nM	CHEMBL_ACT_24759546
CCNT1	7.7	IC50	20	nM	CHEMBL_ACT_24759587
CDK1	7.7	IC50	20	nM	CHEMBL_ACT_24993209
CDK2	7.7	IC50	20	nM	CHEMBL_ACT_24993215
CDK4	7.7	IC50	20	nM	CHEMBL_ACT_24993230
CDK6	7.7	IC50	20	nM	CHEMBL_ACT_24993236
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_24993240
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_25062192
CDK9	7.7	IC50	20	nM	CHEMBL_ACT_3420190
CDK7	7.64	Kd	23	nM	CHEMBL_ACT_2903823
CDK7	7.64	Kd	23	nM	CHEMBL_ACT_7579512
CDK1	7.57	IC50	27	nM	CHEMBL_ACT_16737218
MAK	7.55	Kd	28	nM	CHEMBL_ACT_7579695
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_13914204
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_16610777
CCNB2	7.52	IC50	30	nM	CHEMBL_ACT_182052
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_18784880
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_19027200
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_19112054
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_19258236
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_224601
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_22758192
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_22930617
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_24708390
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_24789101
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_24975167
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_24984402
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_25062180
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_25073415
CCNB2	7.52	IC50	30	nM	CHEMBL_ACT_253440
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_25539583
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_25980855
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_29252794
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_3420187
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_3438052
CDK1	7.52	IC50	30	nM	CHEMBL_ACT_3446977
CCNB2	7.52	IC50	30	nM	CHEMBL_ACT_522220
TYK2	7.46	Kd	35	nM	CHEMBL_ACT_7579580
CDK4	7.42	IC50	38	nM	CHEMBL_ACT_26327830
CDK2	7.4	Ki	40	nM	CHEMBL_ACT_19112048
CDK1	7.4	Ki	40	nM	CHEMBL_ACT_19112064
CDK4	7.4	Ki	40	nM	CHEMBL_ACT_19112065
CDK4	7.4	IC50	40	nM	CHEMBL_ACT_26281851
CDK2	7.4	IC50	40	nM	CHEMBL_ACT_3420188
CDK1	7.39	Ki	41	nM	CHEMBL_ACT_26224832
CDK5	7.37	Kd	43	nM	CHEMBL_ACT_1650017
CDK4	7.26	EC50	55	nM	CHEMBL_ACT_26281885
TNNI3K	7.26	Kd	55	nM	CHEMBL_ACT_2896731
TNNI3K	7.26	Kd	55	nM	CHEMBL_ACT_7581691
EIF2AK1	7.24	Kd	58	nM	CHEMBL_ACT_17898665
CDK19	7.24	Kd	57	nM	CHEMBL_ACT_2901375
CDK19	7.24	Kd	57	nM	CHEMBL_ACT_7581688
CDK5	7.22	IC50	60	nM	CHEMBL_ACT_10882649
CDK6	7.22	IC50	60	nM	CHEMBL_ACT_22758217
CDK6	7.22	IC50	60	nM	CHEMBL_ACT_24789028
CDK6	7.22	IC50	60	nM	CHEMBL_ACT_24975150

Target pathways

Aggregated over 2 target gene(s): CDK2, CDK4.

Top Reactome pathways

94 total, by targets touching each:

Pathway	Targets	Genes
Developmental Biology	2	CDK2, CDK4
Reproduction	2	CDK2, CDK4
Meiosis	2	CDK2, CDK4
Signal Transduction	2	CDK2, CDK4
Cell Cycle	2	CDK2, CDK4
Disease	2	CDK2, CDK4
SCF(Skp2)-mediated degradation of p27/p21	2	CDK2, CDK4
Generic Transcription Pathway	2	CDK2, CDK4
Cellular responses to stress	2	CDK2, CDK4
Senescence-Associated Secretory Phenotype (SASP)	2	CDK2, CDK4
Cellular Senescence	2	CDK2, CDK4
Mitotic G1 phase and G1/S transition	2	CDK2, CDK4
Cyclin E associated events during G1/S transition	2	CDK2, CDK4
G1/S Transition	2	CDK2, CDK4
Cyclin D associated events in G1	2	CDK2, CDK4
G1 Phase	2	CDK2, CDK4
S Phase	2	CDK2, CDK4
Cell Cycle, Mitotic	2	CDK2, CDK4
Cyclin A:Cdk2-associated events at S phase entry	2	CDK2, CDK4
RNA Polymerase II Transcription	2	CDK2, CDK4
Gene expression (Transcription)	2	CDK2, CDK4
Signaling by PTK6	2	CDK2, CDK4
PTK6 Regulates Cell Cycle	2	CDK2, CDK4
Cellular responses to stimuli	2	CDK2, CDK4
Signaling by Non-Receptor Tyrosine Kinases	2	CDK2, CDK4
Meiotic recombination	2	CDK2, CDK4
Transcriptional regulation of granulopoiesis	2	CDK2, CDK4
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	2	CDK2, CDK4
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	2	CDK2, CDK4
Diseases of mitotic cell cycle	2	CDK2, CDK4
Aberrant regulation of mitotic cell cycle due to RB1 defects	2	CDK2, CDK4
Hemostasis	1	CDK2
G0 and Early G1	1	CDK2
Telomere Maintenance	1	CDK2
Telomere Extension By Telomerase	1	CDK2
APC/C-mediated degradation of cell cycle proteins	1	CDK2
Activation of ATR in response to replication stress	1	CDK2
Regulation of APC/C activators between G1/S and early anaphase	1	CDK2
Extension of Telomeres	1	CDK2
Oxidative Stress Induced Senescence	1	CDK4
Oncogene Induced Senescence	1	CDK4
DNA Damage/Telomere Stress Induced Senescence	1	CDK2
RMTs methylate histone arginines	1	CDK4
Chromatin modifying enzymes	1	CDK4
Transcriptional Regulation by TP53	1	CDK2
Transcriptional regulation of white adipocyte differentiation	1	CDK4
Mitotic G2-G2/M phases	1	CDK2
Regulation of mitotic cell cycle	1	CDK2
Chromatin organization	1	CDK4
Regulation of TP53 Activity	1	CDK2

Dominant GO biological processes

GO term	Targets
G1/S transition of mitotic cell cycle	2
protein phosphorylation	2
signal transduction	2
positive regulation of cell population proliferation	2
regulation of G2/M transition of mitotic cell cycle	2
regulation of gene expression	2
cell division	2
G2/M transition of mitotic cell cycle	1
negative regulation of transcription by RNA polymerase II	1
DNA replication	1
DNA repair	1
chromatin remodeling	1
DNA-templated transcription	1
potassium ion transport	1
centriole replication	1

Indications & clinical

Indications

16 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
lymphoma	2	MONDO:0005062	EFO:0000574
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
sarcoma	2	MONDO:0005089	EFO:0000691
prolymphocytic leukemia	2	MONDO:0001023	MONDO:0001023
kidney cancer	2	MONDO:0002367	MONDO:0002367
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
neoplasm	1	MONDO:0005070	EFO:0000616
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
leukemia	1	MONDO:0005059	EFO:0000565
male breast carcinoma	1	MONDO:0005628	EFO:0006861
breast neoplasm	1	MONDO:0021100	MONDO:0007254
lymphoid leukemia	1	MONDO:0005402	EFO:0004289

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 58.

Phase distribution

Phase	Trials
PHASE1	30
PHASE2	23
PHASE1/PHASE2	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003039	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma
NCT00003256	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Recurrent Prostate Cancer
NCT00003620	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
NCT00005074	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma
NCT00005971	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
NCT00005974	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT00006245	PHASE2	COMPLETED	Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
NCT00016016	PHASE1/PHASE2	COMPLETED	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
NCT00016939	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00020189	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00020332	PHASE1/PHASE2	COMPLETED	Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00023894	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00047203	PHASE2	COMPLETED	Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00058240	PHASE1/PHASE2	COMPLETED	Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00083122	PHASE2	COMPLETED	Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00087282	PHASE2	COMPLETED	Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
NCT00098371	PHASE2	TERMINATED	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00112723	PHASE1/PHASE2	TERMINATED	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00331682	PHASE2	COMPLETED	Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
NCT00407966	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00445341	PHASE1/PHASE2	COMPLETED	Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
NCT00464633	PHASE2	COMPLETED	Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
NCT00634244	PHASE2	COMPLETED	Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00795002	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00991952	PHASE2	COMPLETED	Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
NCT01349972	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02520011	PHASE2	TERMINATED	Alvocidib Biomarker-driven Phase 2 AML Study
NCT03969420	PHASE2	TERMINATED	Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
NCT00003004	PHASE1	COMPLETED	Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
NCT00003690	PHASE1	COMPLETED	Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00006485	PHASE1	COMPLETED	Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00007917	PHASE1	COMPLETED	Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
NCT00012181	PHASE1	COMPLETED	Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
NCT00016185	PHASE1	COMPLETED	Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00019344	PHASE1	COMPLETED	Flavopiridol in Treating Patients With Refractory Cancer
NCT00021073	PHASE1	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00039455	PHASE1	TERMINATED	Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
NCT00042874	PHASE1	COMPLETED	Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00045448	PHASE1	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00046917	PHASE1	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00047307	PHASE1	COMPLETED	Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
NCT00058227	PHASE1	COMPLETED	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
NCT00064285	PHASE1	COMPLETED	Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
NCT00070239	PHASE1	TERMINATED	Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
NCT00072436	PHASE1	COMPLETED	Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
NCT00079352	PHASE1	COMPLETED	Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00080990	PHASE1	COMPLETED	Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
NCT00094978	PHASE1	TERMINATED	Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
NCT00098579	PHASE1	COMPLETED	Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
NCT00101231	PHASE1	TERMINATED	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
NCT00112684	PHASE1	TERMINATED	Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00278330	PHASE1	COMPLETED	Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
NCT00324480	PHASE1	COMPLETED	Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
NCT00377104	PHASE1	TERMINATED	Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00470197	PHASE1	COMPLETED	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
NCT03298984	PHASE1	COMPLETED	Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03441555	PHASE1	COMPLETED	A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03563560	PHASE1	COMPLETED	A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

86 molecules share ≥1 primary target. Top 86 by shared-target count:

Molecule	Source	Status	Shared targets
ABEMACICLIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
CERITINIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
DABRAFENIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
GILTERITINIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
NINTEDANIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
PALBOCICLIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
RIBOCICLIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
TRILACICLIB	ChEMBL	Phase 4 (approved)	CDK2, CDK4
DINACICLIB	ChEMBL	Phase 3	CDK2, CDK4
LEROCICLIB	ChEMBL	Phase 3	CDK2, CDK4
LESTAURTINIB	ChEMBL	Phase 3	CDK2, CDK4
QUERCETIN	ChEMBL	Phase 3	CDK2, CDK4
AT-7519	ChEMBL	Phase 2	CDK2, CDK4
CROZBACICLIB	ChEMBL	Phase 2	CDK2, CDK4
CT-7001	ChEMBL	Phase 2	CDK2, CDK4
CULMERCICLIB	ChEMBL	Phase 2	CDK2, CDK4
CYC-065	ChEMBL	Phase 2	CDK2, CDK4
EBVACICLIB	ChEMBL	Phase 2	CDK2, CDK4
ELLAGIC ACID	ChEMBL	Phase 2	CDK2, CDK4
INDIRUBIN	ChEMBL	Phase 2	CDK2, CDK4
INIXACICLIB	ChEMBL	Phase 2	CDK2, CDK4
ISTISOCICLIB	ChEMBL	Phase 2	CDK2, CDK4
LY-2090314	ChEMBL	Phase 2	CDK2, CDK4
MILCICLIB	ChEMBL	Phase 2	CDK2, CDK4
NARAZACICLIB	ChEMBL	Phase 2	CDK2, CDK4
REBASTINIB	ChEMBL	Phase 2	CDK2, CDK4
RG-547	ChEMBL	Phase 2	CDK2, CDK4
RIVICICLIB	ChEMBL	Phase 2	CDK2, CDK4
RONICICLIB	ChEMBL	Phase 2	CDK2, CDK4
SELICICLIB	ChEMBL	Phase 2	CDK2, CDK4
TEGTOCICLIB	ChEMBL	Phase 2	CDK2, CDK4
ULECACICLIB	ChEMBL	Phase 2	CDK2, CDK4
VORUCICLIB	ChEMBL	Phase 2	CDK2, CDK4
ZEMIRCICLIB	ChEMBL	Phase 2	CDK2, CDK4
Afatinib	PubChem	Approved	CDK2, CDK4
Binimetinib	PubChem	Approved	CDK2, CDK4
Crizotinib	PubChem	Approved	CDK2, CDK4
dacomitinib	PubChem	Approved	CDK2, CDK4
Fostamatinib	PubChem	Approved	CDK2, CDK4
Idelalisib	PubChem	Approved	CDK2, CDK4
Pazopanib	PubChem	Approved	CDK2, CDK4
regorafenib	PubChem	Approved	CDK2, CDK4
Selumetinib	PubChem	Approved	CDK2, CDK4
Trametinib	PubChem	Approved	CDK2, CDK4
ENCORAFENIB	ChEMBL	Phase 4 (approved)	CDK4
ERLOTINIB	ChEMBL	Phase 4 (approved)	CDK2
FEDRATINIB	ChEMBL	Phase 4 (approved)	CDK4
LAPATINIB	ChEMBL	Phase 4 (approved)	CDK2
MOMELOTINIB	ChEMBL	Phase 4 (approved)	CDK2
PACRITINIB	ChEMBL	Phase 4 (approved)	CDK2
QUIZARTINIB	ChEMBL	Phase 4 (approved)	CDK2
SORAFENIB	ChEMBL	Phase 4 (approved)	CDK2
SUNITINIB	ChEMBL	Phase 4 (approved)	CDK4
6-O-BENZYLGUANINE	ChEMBL	Phase 3	CDK2
CRENOLANIB	ChEMBL	Phase 3	CDK2
DALPICICLIB	ChEMBL	Phase 3	CDK4
DEFACTINIB	ChEMBL	Phase 3	CDK2
DOVITINIB	ChEMBL	Phase 3	CDK4
ENZASTAURIN	ChEMBL	Phase 3	CDK2
INDIGO	ChEMBL	Phase 3	CDK2
RUBOXISTAURIN	ChEMBL	Phase 3	CDK4
SARACATINIB	ChEMBL	Phase 3	CDK2
ASNUCICLIB	ChEMBL	Phase 2	CDK2
AT-9283	ChEMBL	Phase 2	CDK4
ATIRMOCICLIB	ChEMBL	Phase 2	CDK4
BI-2536	ChEMBL	Phase 2	CDK4
BMS-754807	ChEMBL	Phase 2	CDK2
BMS-919373	ChEMBL	Phase 2	CDK2
CENISERTIB	ChEMBL	Phase 2	CDK2
CLOSANTEL	ChEMBL	Phase 2	CDK2
DANUSERTIB	ChEMBL	Phase 2	CDK2
ECIRUCICLIB	ChEMBL	Phase 2	CDK4
FISETIN	ChEMBL	Phase 2	CDK2
LAUROGUADINE	ChEMBL	Phase 2	CDK2
LUTEOLIN	ChEMBL	Phase 2	CDK2
R-406	ChEMBL	Phase 2	CDK2
SALIRASIB	ChEMBL	Phase 2	CDK2
SILMITASERTIB	ChEMBL	Phase 2	CDK2
SIMUROSERTIB	ChEMBL	Phase 2	CDK2
SOTRASTAURIN	ChEMBL	Phase 2	CDK2
SU-014813	ChEMBL	Phase 2	CDK4
UCN-01	ChEMBL	Phase 2	CDK2
ZOTIRACICLIB	ChEMBL	Phase 2	CDK2
corydine	PubChem	Approved	CDK2
Gefitinib	PubChem	Approved	CDK4
Pomalidomide	PubChem	Approved	CDK4